Characterization of a human colorectal carcinoma cell line with acquired resistance to flavopiridol

Molecular Pharmacology

Volumn 60, Issue 5, 2001, Pages 885-893

  Smith, Victoria ^a   Raynaud, Florence ^a   Workman, Paul ^a   Kelland, Lloyd R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

9 NITROPAULLONE; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; DOXORUBICIN; ETOPOSIDE; FLAVOPIRIDOL; GLYCOPROTEIN P; HYMENIALDISINE; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; PURVALANOL A; RALTITREXED; ROSCOVITINE; TOPOTECAN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; COLORECTAL CARCINOMA; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CROSS RESISTANCE; DRUG ACCUMULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PHOSPHORYLATION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

EID: 0034752936     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.60.5.885     Document Type: Article

References (39)

1. Flavopiridol binds to duplex DNA
2. Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol
3. Flavopiridol: A cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells
4. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: The importance of sequence of administration
5. A family of drug transporters: The multidrug resistance-associated proteins
6. Cell cycle-independent induction of apoptosis by the anti-tumor drug flavopiridol in endothelial cells
7. Flavopiridel induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells
8. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication
9. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP
10. Antitumoral activity of flavone L 86-8275
11. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase
12. Inhibitors of cyclin-dependent kinases as therapeutic agents for the treatment of cancer
13. P-glycoprotein - A mediator of multidrug resistance in tumor cells
14. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors
15. Genes that modulate apoptosis: Major determinants of drug resistance
16. Development of a bicistronic vector driven by human polypeptide chain elongation factor 1alpha promoter for creation of stable mammalian cell lines that express very high levels of recombinant proteins
17. Modulation by (iso)flavonoids of the ATPase activity of the multidrug resistance protein
18. Potent interaction of flavopiridol with MRP1
19. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275
20. Novel small molecule alpha v integrin antagonists: Comparative anti-cancer efficacy with known angiogenesis inhibitors
21. Cyclin E, a potential prognostic marker for breast cancer
22. Indirubins inhibit glycogen synthase kinase 3beta and CDK5/P25, two protein kinases involved in abnormal Tau phosphorylation in Alzheimer's disease
23. Induction of growth inhibition and apoptosis in prostate cancer cells by flavopiridol
24. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5
25. Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent
26. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes
27. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
28. Improved programme for the analysis of DNA histograms
29. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis
30. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (MXP/BCRP/ABCP1), in flavopiridol-resistant human breast cancer cells
31. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms
32. Effects of new anti-oestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines
33. Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines
34. New colorimetric cytotoxicity assay for anticancer-drug screening
35. Deregulated cyclin E induces chromosomal instability
36. Resistance to cytostatic drugs at the cellular level
37. Discovery initial characterization of the paullones a novel class of small-molecule inhibitors of cyclin-dependent kinases